New shot before surgery aims to boost immune attack on pancreatic cancer

NCT ID NCT07024615

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 32 times

Summary

This early study tests a new drug, ASP2138, given as a shot two weeks before surgery for people with a type of pancreatic cancer that has a specific protein (CLDN18.2). After surgery, patients receive standard chemotherapy for up to six months. The main goal is to check safety and side effects in 25 adults with resectable tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke University Medical Center - Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

PANCREATIC DUCTAL ADENOCARCINOMA PANCREATIC DUCTAL ADENOCARCINOMA